Sign in
SLRN Stock Price, Chart, Stats & News
Acelyrin, Inc.
Save
229.17M
Market cap
–
Current P/E
–
Forward P/E
SLRN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 19.01% |
Operating margin | -58571.35% |
Pretax margin | -53463.45% |
Net margin | -53463.45% |
Effective tax rate | – |
ROA | -41.89% |
ROE | -39.36% |
D/E | 0.01x |
Interest coverage ratio | – |
SLRN valuation
P/E | – |
P/S | 670.07x |
P/B | 0.56x |
P/CF | -0.96x |
P/FCF | -0.96x |
P/OCF | -0.96x |
PEG | 0.17x |
EV multiple | -2.13x |
About
Acelyrin, Inc. is a biopharmaceutical company focused on discovering, obtaining, and rapidly advancing the development and commercialization of innovative medical therapies. The firm's most advanced experimental drug is izokibep, a potent small protein therapeutic specifically designed to block IL-17A. This compound is currently undergoing Phase 3 clinical evaluations for its use in treating Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis.
Similar securities
Based on sector and market capitalization
Report issue